
==========================================================================================
LINEAR CPSS TEST: Paper-conform ElasticNet implementation
==========================================================================================

Changes from old implementation:
  1. q is FIXED (not adaptive)
  2. λ is tuned to achieve |Ŝ| ≈ q on EACH subsample
  3. NO invalid unimodality tests
  4. Only worst-case bound (always valid)
==========================================================================================
DRUG: Erlotinib (Linear CPSS, paper-conform)
==========================================================================================

Expected biomarkers (7):
  - MUT__EGFR: EGFR mutations (primary target)
  - CNV__EGFR: EGFR amplification
  - TPM__EGFR: EGFR expression
  - MUT__KRAS: KRAS resistance
  - MUT__BRAF: BRAF resistance
  - TPM__MET: MET bypass
  - CNV__MET: MET amplification

Data: n=821, d=489, l=24, q=96

Running paper-conform Linear CPSS with B=10 pairs...
Running CPSS with B=10 pairs, target q=96, method=elasticnet
  Pair 1/10... A1:95 A2:92
  Pair 2/10... A1:96 A2:99
  Pair 3/10... A1:96 A2:95
  Pair 4/10... A1:94 A2:96
  Pair 5/10... A1:99 A2:97
  Pair 6/10... A1:99 A2:97
  Pair 7/10... A1:92 A2:101
  Pair 8/10... A1:96 A2:96
  Pair 9/10... A1:93 A2:95
  Pair 10/10... A1:96 A2:96
Observed q̂ = 96.0 (target was q=96)

Results:
  q̂ = 96.0 (target: 96)
  θ = 0.1963
  τ* (worst-case) = 0.893
  Features passing τ*: 4

------------------------------------------------------------------------------------------
Top 15 Features:
------------------------------------------------------------------------------------------
  TPM__VWA8                                Π̂=1.000
  TPM__TFF3                                Π̂=0.950
  TPM__VAV3                                Π̂=0.950
✓ MUT__EGFR                                Π̂=0.900
  TPM__KLF9                                Π̂=0.850
  TPM__ADGRF4                              Π̂=0.850
  TPM__STK32A                              Π̂=0.800
  TPM__DYNLT3                              Π̂=0.800
  TPM__ARMCX2                              Π̂=0.750
  TPM__PLXND1                              Π̂=0.750
  TPM__SLC7A5                              Π̂=0.750
  TPM__CNRIP1                              Π̂=0.750
  METH__LHFPL2                             Π̂=0.700
  TPM__FAM50A                              Π̂=0.700
  TPM__APBB1                               Π̂=0.700

------------------------------------------------------------------------------------------
Biomarker Validation:
------------------------------------------------------------------------------------------
✓✓ MUT__EGFR            Rank 348, Π̂=0.900 - EGFR mutations (primary target)
✗  CNV__EGFR            NOT FOUND - EGFR amplification
✗  TPM__EGFR            NOT FOUND - EGFR expression
✗  MUT__KRAS            NOT FOUND - KRAS resistance
✗  MUT__BRAF            NOT FOUND - BRAF resistance
✗  TPM__MET             NOT FOUND - MET bypass
✗  CNV__MET             NOT FOUND - MET amplification

Strong (Π̂≥0.5): 1/7
Weak (Π̂≥0.1): 0/7
Total: 1/7 (14.3%)


==========================================================================================
DRUG: Cisplatin (Linear CPSS, paper-conform)
==========================================================================================

Expected biomarkers (8):
  - MUT__TP53: TP53 (apoptosis)
  - MUT__ERCC1: ERCC1 (NER)
  - MUT__ERCC2: ERCC2 (NER helicase)
  - MUT__MSH2: MSH2 (MMR)
  - MUT__MLH1: MLH1 (MMR)
  - MUT__BRCA1: BRCA1 (HR)
  - MUT__BRCA2: BRCA2 (HR)
  - MUT__KRAS: KRAS (resistance)

Data: n=667, d=410, l=20, q=80

Running paper-conform Linear CPSS with B=10 pairs...
Running CPSS with B=10 pairs, target q=80, method=elasticnet
  Pair 1/10... A1:80 A2:77
  Pair 2/10... A1:83 A2:79
  Pair 3/10... A1:80 A2:78
  Pair 4/10... A1:79 A2:79
  Pair 5/10... A1:78 A2:78
  Pair 6/10... A1:78 A2:78
  Pair 7/10... A1:81 A2:81
  Pair 8/10... A1:82 A2:79
  Pair 9/10... A1:77 A2:77
  Pair 10/10... A1:78 A2:81
Observed q̂ = 79.2 (target was q=80)

Results:
  q̂ = 79.2 (target: 80)
  θ = 0.1930
  τ* (worst-case) = 0.882
  Features passing τ*: 7

------------------------------------------------------------------------------------------
Top 15 Features:
------------------------------------------------------------------------------------------
  TPM__SLFN11                              Π̂=1.000
  TPM__BMP4                                Π̂=1.000
  TPM__APLP2                               Π̂=0.950
  TPM__CUEDC1                              Π̂=0.950
  TPM__SLC38A5                             Π̂=0.950
  TPM__RPL10A                              Π̂=0.900
  TPM__PDCD6IP-DT                          Π̂=0.900
  TPM__SQSTM1                              Π̂=0.850
  TPM__MOB3A                               Π̂=0.850
  TPM__LINC01410                           Π̂=0.850
  TPM__ATF5                                Π̂=0.800
  TPM__TPD52L1                             Π̂=0.800
  TPM__PKP3                                Π̂=0.800
  TPM__ZBED4                               Π̂=0.750
  TPM__TMEM191A                            Π̂=0.750

------------------------------------------------------------------------------------------
Biomarker Validation:
------------------------------------------------------------------------------------------
✗  MUT__TP53            NOT FOUND - TP53 (apoptosis)
✗  MUT__ERCC1           NOT FOUND - ERCC1 (NER)
✗  MUT__ERCC2           NOT FOUND - ERCC2 (NER helicase)
✗  MUT__MSH2            NOT FOUND - MSH2 (MMR)
✗  MUT__MLH1            NOT FOUND - MLH1 (MMR)
✗  MUT__BRCA1           NOT FOUND - BRCA1 (HR)
✗  MUT__BRCA2           NOT FOUND - BRCA2 (HR)
✗  MUT__KRAS            NOT FOUND - KRAS (resistance)

Strong (Π̂≥0.5): 0/8
Weak (Π̂≥0.1): 0/8
Total: 0/8 (0.0%)


==========================================================================================
DRUG: Dabrafenib (Linear CPSS, paper-conform)
==========================================================================================

Expected biomarkers (4):
  - MUT__BRAF: BRAF V600E (primary target)
  - MUT__NRAS: NRAS (MAPK pathway)
  - MUT__KRAS: KRAS (MAPK pathway)
  - TPM__BRAF: BRAF expression

Data: n=822, d=489, l=24, q=96

Running paper-conform Linear CPSS with B=10 pairs...
Running CPSS with B=10 pairs, target q=96, method=elasticnet
  Pair 1/10... A1:97 A2:92
  Pair 2/10... A1:99 A2:94
  Pair 3/10... A1:92 A2:95
  Pair 4/10... A1:96 A2:96
  Pair 5/10...